Loading cancer entity…
Loading cancer entity…
Clinical trials
62 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01799538 | Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis | recruiting | Phase 1 / Phase 2 | 100 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 |
| clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03304678 | Discovery of Sirolimus Sensitive Biomarkers in Blood | completed | Phase 2 | 33 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05467397 | Feasibility of [11C]Acetate-PET in LAM and TSC | active not recruiting | Phase 1 / Phase 2 | 7 | Brigham and Women's HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT01353209 | Letrozole for Lymphangioleiomyomatosis(TRAIL) | completed | Phase 2 | 17 | University of CincinnatiOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT02494570 | A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa(AMPECT) | completed | Phase 2 | 34 | Aadi Bioscience, Inc.INDUSTRY | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03253913 | Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial(RESULT) | completed | Phase 2 | 25 | University of CincinnatiOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05625919 | A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa) | unknown | Phase 1 / Phase 2 | 54 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT03062943 | A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)(LAM) | completed | Phase 2 | 30 | IRCCS MultimedicaOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT00126672 | RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05190627 | Effect of Loratadine in Lymphangioleiomyomatosis(LORALAM) | unknown | Phase 2 | 62 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT02484664 | COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC(COLA) | completed | Phase 2 | 12 | Brigham and Women's HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT01059318 | A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis | completed | Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 3 | Nov 19, 2020 | clinicaltrials |
| NCT02061397 | Safety of Simvastatin in LAM and TSC(SOS) | completed | Phase 1 / Phase 2 | 10 | University of PennsylvaniaOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT03131999 | LAM Pilot Study With Imatinib Mesylate(LAMP-1) | completed | Phase 1 / Phase 2 | 18 | Medical University of South CarolinaOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT00457964 | RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM | completed | Phase 1 / Phase 2 | 36 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT01690871 | A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00005906 | Treatment With Octreotide in Patients With Lymphangioleiomyomatosis | completed | Phase 2 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 30, 2010 | clinicaltrials |
| NCT00490789 | Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM(TESSTAL) | unknown | Phase 2 | 14 | Cardiff UniversityOTHER | 1 | Apr 30, 2008 | clinicaltrials |
| NCT00457808 | Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM | completed | Phase 2 | 25 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 9, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Aug 31, 2026source: clinicaltrials